Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 21;23(1-2):13-20.
doi: 10.3727/096504015X14410238486766.

Tumor-Suppressor Gene NBPF1 Inhibits Invasion and PI3K/mTOR Signaling in Cervical Cancer Cells

Yun Qin  1 , Xicai Tang, Mingxing Liu
Affiliations

Tumor-Suppressor Gene NBPF1 Inhibits Invasion and PI3K/mTOR Signaling in Cervical Cancer Cells

Yun Qin et al. Oncol Res. .

Abstract

The purpose of this study was to assess the effects of NBPF1 expression on cervical cancer cell invasion and apoptosis and to illustrate its potential mechanism. Human cervical cancer HeLa cells were transfected with the constructed siNBPF1 or pcDNA3.1-NBPF1 vectors. Effects of NBPF1 expression on cell invasion ability and cell apoptosis were analyzed using the Matrigel method and an Annexin V-FITC cell apoptosis kit, respectively. In addition, cell apoptosis-related proteins involved with the PI3K/mTOR signaling pathway were analyzed using Western blot. Remediation experiments were conducted to verify the effects of NBPF1 expression on cell invasion and apoptosis. Compared to the control, mRNA and protein expressions of NBPF1 were significantly decreased when cells were transfected with siNBPF1 (p < 0.05), which was contrary to the results of cells transfected with pcDNA3.1-NBPF1. Overexpression of NBPF1 significantly suppressed HeLa cell invasion but promoted cell apoptosis (p < 0.05). Overexpression of NBPF1 performed a significant inhibitory role on PI3K/mTOR signal pathway expression, while NBPF1 was silenced, showing contrary results. Our data suggested that NBPF1 overexpression may be a suppressor for cervical cancer via affecting cell invasion and apoptosis through regulating PI3K/mTOR signaling pathway. NBPF1 may be a potential therapeutic target for cervical cancer treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of NBPF1 in HeLa cells transfected with different plasmas. (A) mRNA and protein expressions of NBPF1 were increased when cells were transfected with pcDNA-NBPF1. (B) mRNA and protein expressions of NBPF1 were decreased when cells were transfected with siRNA-NBPF1. *p < 0.05, compared with the control; **p < 0.01, compared with the control group.
Figure 2
Figure 2
Effects of NBPF1 expression on cell migration ability. (A) Downregulation of NBPF1 increased cell migration. (B) NBPF1 overexpression suppressed cell migration ability. *p < 0.05, compared with the control.
Figure 3
Figure 3
Influence of NBPF1 expressions on cell apoptosis. (A) Silenced NBPF1 had no significant influence on cell apoptosis. (B) NBPF1 overexpression promoted cell apoptosis. **p < 0.01, compared with the control group.
Figure 4
Figure 4
Remediation experiments of NBPF1 expression on cell biological process. (A) Coexpression of silencing and overexpression of NBPF1 had no significant effects on cell migration. (B) Coexpression of silenced and overexpression of NBPF1 had no significant effects on cell apoptosis. (C, D) Cell apoptosis in control and experimental group. (E) Migrating cells in each group when siNBPF1 expression was inhibited by inhibitor. (F) Cell apoptosis-related protein expression in each group; **p < 0.01, compared with the control group.
Figure 5
Figure 5
Effects of NBPF1 expression on cell apoptotic-related proteins in HeLa cells. (A) Silencing NBPF1 contributed to expressions of p-mTOR, p-PI3K, p-P70 compared with the controls. (B) NBPF1 overexpression suppressed expressions of p-mTOR, p-PI3K, p-P70 compared with the controls.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Centers for Disease Control and Prevention: Cervical cancer screening among women aged 18–30 years-United States, 2000–2010. Morb. Mortal. Wkly. Rep. 61:1038; 2013. - PubMed
    1. Siegel R.; Ma J.; Zou Z.; Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64:9–29; 2014. - PubMed
    1. Angioli R.; Plotti F.; Montera R.; Aloisi A.; Luvero D.; Capriglione S.; Terranova C.; Nardone C. D. C.; Muzii L.; Benedetti-Panici P. Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. Gynecol. Oncol. 127:290–296; 2012. - PubMed
    1. Katsumata N.; Yoshikawa H.; Kobayashi H.; Saito T.; Kuzuya K.; Nakanishi T.; Yasugi T.; Yaegashi N.; Yokota H.; Kodama S. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: A Japan Clinical Oncology Group trial (JCOG 0102). Br. J. Cancer 108:1957–1963; 2013. - PMC - PubMed
    1. Halec G.; Alemany L.; Lloveras B.; Schmitt M.; Alejo M.; Bosch F.; Tous S.; Klaustermeier J.; Guimera N.; Grabe N.; Lahrhamm B.; Gissmann L.; Quint W.; Bosch F. X.; De Sanjose S.; Pawlita M. Pathogenic role of eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J. Pathol. 234:441–451; 2014. - PubMed